Lantheus (LNTH – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Turkaly from JMP Securities reiterated a Buy rating on the stock and has a $112.00 price target.
David Turkaly has given his Buy rating due to a combination of factors that highlight Lantheus’s strong financial performance and strategic positioning. The company’s fourth-quarter results surpassed expectations in both revenue and profit, with significant growth in free cash flow and share repurchases, indicating robust financial health. Additionally, Lantheus’s strategic acquisitions and reaffirmed guidance for 2024 have alleviated investor concerns about potential declines in PYLARIFY pricing and volumes.
Moreover, the company’s outlook for 2025 was more optimistic than anticipated, boosting investor confidence and driving a notable increase in stock value. Lantheus is also poised for sustained double-digit growth from 2026, led by PYLARIFY, which remains a key growth driver. Furthermore, potential royalty opportunities from partnerships with GE and Curium could contribute to future growth, enhancing the company’s long-term prospects. Despite these positive developments, the stock is considered undervalued compared to its high-growth peers, making it an attractive investment opportunity.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $110.00 price target.